Neovirtech
NeoVirTech is a French biotechnology CRO offering proprietary ANCHOR™ DNA tagging technology for real-time visualization of viral infection in living cells, serving pharmaceutical, biotech, medical device, defense, and academic customers with antiviral discovery, oncolytic virotherapy development, and disinfection testing services.
- Company typePrivate
- Founded2014
- HeadquartersToulouse, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Neovirtech does
NeoVirTech SAS is a French biotechnology Contract Research Organization (CRO) founded in February 2014 and headquartered at the Oncopole campus in Toulouse, with an additional R&D laboratory at the Toulouse Cancer Research Center (CRCT) opened in 2022. The company commercializes its proprietary ANCHOR™ DNA tagging technology — a system that fuses a short non-repetitive ANCH sequence with an OR-fluorescent protein to convert any dsDNA virus or vector into an autofluorescent particle, enabling autonomous real-time visualization of viral infection and replication in living cells without fixation, extraction, or staining. Multiple ANCHOR™ systems (up to four colors) can be operated simultaneously for co-infection studies, and the company maintains a catalog of 32 ANCHOR-tagged viruses spanning human, animal, and biodefense applications. Core technical infrastructure includes dual BSL2/BSL3 containment, automated CellInsight CX7 HCS high-content screening, pipetting robots, and a 22TB secured server, all of which underwrite both internal R&D and customer service delivery.
The company monetizes through three revenue streams: (1) CRO services — antiviral discovery (compound screening, mechanism-of-action studies, SAR optimization, in vivo validation against a 1,200 FDA-approved compound library), oncolytic virotherapy development (design, cell line testing, in vivo testing, drug combinations, virogram analysis), disinfection efficacy testing (chemical, UV-C, ozone, radiative on surfaces and living skin), and high-resolution imaging; (2) ANCHOR™ technology licensing via Material Transfer Agreements in tiered packs (Discovery €1,000, Complete €2,000, Advanced €4,000) for perpetual use; and (3) proprietary antiviral compound development (notably the LAVR-289 family and nitrocorroles) for out-licensing. Customer acquisition is sales-led, supported by industry conference participation (Eurosatory, ICAR), scientific publication, technology transfer partnerships (SAYENS, Toulouse Tech Transfer), and strategic alliances with VirexpR, VirHealth, Imactiv-3D, and BioImmunitas.
NeoVirTech serves pharmaceutical and biotechnology companies, oncology developers, medical device and disinfection manufacturers, government and defense agencies (notably French Armed Forces for poxvirus countermeasures), gene therapy developers, and academic institutions — a horizontal segmentation across approximately 86 worldwide customers. The company holds 10 patents protecting the ANCHOR™ platform and related compounds, has received successive French innovation grants (I-Lab 2013 and 2016, AID 2020, Occitanie 2021, France 2030 Perseverance 2024), and was recognized by PharmaTech Outlook as a Top 10 European Drug Discovery and Development Company in 2019. Ownership remains private with founder Franck Gallardo as CEO; no private equity backing has been disclosed.
Neovirtech firmographics
Firmographics- Name
- Neovirtech
- Legal name
- NeoVirTech SAS
- Website
- https://neovirtech.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeoVirTech is a French biotechnology CRO offering proprietary ANCHOR™ DNA tagging technology for real-time visualization of viral infection in living cells, serving pharmaceutical, biotech, medical device, defense, and academic customers with antiviral discovery, oncolytic virotherapy development, and disinfection testing services.
- Ownership category
- akta.pro rank
Neovirtech industry classification
Industry- Product category
- Virology Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Neovirtech is headquartered
LocationHeadquarters
- HQ city
- Toulouse
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Neovirtech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CRO Services - Antiviral Discovery: Contract research services for pharmaceutical and biotech companies including compound screening, mechanism of action studies, SAR (Structure-Activity Relationship) studies, and in vivo validation. Multi-year screening and optimization campaigns for public agencies and private companies.
- CRO Services - Disinfection Testing: Testing services for chemical, physical, and radiative disinfection processes on viruses. Calibration and validation of disinfection devices for companies. Normative testing according to FR/EN/ASTM standards through VirHealth partnership.
- CRO Services - Oncolytic Virus Development: Preclinical development services for oncolytic viruses including cell line efficiency testing, in vivo testing, drug combination studies, and virogram analysis on cancer cell lines.
- ANCHOR™ Technology Licensing: Licensing fees for technology access including Discovery Pack (trial version, €1000, 6-month MTA), Complete Pack (all systems, €2000), and Advanced Pack (with autofluorescent virus, €4000). MTA (Material Transfer Agreement) based licensing.
- Proprietary Antiviral Compounds: Development and positioning of proprietary products displaying broad spectrum antiviral activities on emerging markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Discovery Pack (Trial) - €1,000 |
| One time/ perpetual license | Pay-as-you-go | Complete Pack - €2,000 |
| One time/ perpetual license | Pay-as-you-go | Advanced Pack - €4,000 |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Neovirtech product offering
Product offeringCore offering
NeoVirTech SAS is a contract research organization (CRO) that delivers specialized virology research services, including antiviral drug discovery, oncolytic virotherapy development, disinfection efficacy testing, and live-cell imaging, executed in BSL2 and BSL3 laboratories. Its proprietary ANCHOR™ technology enables real-time visualization of DNA in living cells, supporting both fee-for-service research and technology licensing engagements.
Product overview
NeoVirTech operates as a biotechnology CRO offering a platform of services centered on its proprietary ANCHOR™ autofluorescent virus technology. The core offering consists of the ANCHOR™ Technology platform and an expanding collection of 32 ANCHOR™-tagged viruses for real-time visualization of infection and replication. Service modules include antiviral drug discovery (screening through in vivo validation), oncolytic virotherapy development (design through preclinical testing), high content screening platform, high-resolution imaging, and disinfection efficacy testing. The company also offers access to BSL2/BSL3 laboratory facilities. Recent additions include an oncolytic viruses platform and airborne disinfection testing capabilities developed through strategic partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- Antiviral Drug Discovery
Quantifiable outcome
- Visualization of single DNA molecules in living cells (up to 500 OR-FP/ANCH accumulation)
- +4 more outcomes
Companies that use Neovirtech
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles3 records
Neovirtech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Neovirtech partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- VirexpR SAScoreExpanded collaboration to develop experimental test bench model for airborne poxvirus contamination. VirexpR uses VACV ANCHOR poxvirus (labeled 'used by French Armed Forces' in 2024) as mimetic model to characterize infectious bioaerosols using various test benches for air treatment technology evaluation under real conditions.
- Imactiv-3DcoreCollaboration for 3D imaging and analysis of infected spheroids. Imactiv-3D provides imaging expertise and custom algorithms for quantification. Partnership enables complex 3D model analysis including infected spheroids to whole insects.
- ImPACT Team (CRCT)corePart of Perseverance program (France 2030 funded) to develop theranostic platform for cancer virotherapies. Collaboration for preclinical development of oncolytic viruses with arming strategies.
- National Veterinary School of Toulouse (ENVT)corePart of Perseverance program for cancer virotherapy development. Long-standing collaboration for application of ANCHOR technology to poxviruses of veterinary interest and animal herpesvirus tagging.
- CHU de Toulouse / Oncopole Claudius RégaudcoreClinical partner in Perseverance program (France 2030) for theranostic platform development. Provides patient tumor organoid models and clinical expertise for oncolytic virotherapy validation.
- VirexpR SAScoreStrategic alliance combining NeoVirTech's autofluorescent viruses with VirexpR's nebulization technologies for airborne disinfection testing. Uses VirexpR's 2.5m³ and 20m³ nebulization chambers to disperse VACV ANCHOR poxvirus and measure air treatment device efficiency using image-based readout. Partnership allows measurement and visualization of airborne disinfection efficacy and respiratory protection testing.
- BioImmunitas LtdcoreLong-term partnership to advance BioImmunitas's human recombinant protein (hRP) therapeutic platform using NeoVirTech's antiviral discovery platform to position the therapeutic on anti-viral market. BioImmunitas utilizes NVT's proprietary platform for antiviral compound testing and validation.
- Teco LabsminorPartnership agreement signed in 2023 to develop NeoVirTech's activity in the Asian market through distribution and partnership facilitation.
- Cancer Research Center of Toulouse (CRCT)coreNeoVirTech opened laboratory at CRCT to structure anti-cancer programs toward patient-oriented theranostics platform. Collaboration with CRCT Team 10 to develop rapid theranostic platform for oncolytic virotherapy efficacy. Long-term collaboration to ensure patient benefits and reduce time to decision for individualized cancer therapies.
- VirHealth SAScoreStrategic alliance creating one of the most advanced private virus disinfection platforms in Europe. Combines virology expertise to provide customers with extended virus disinfection measurement and R&D platform. Focus on virus persistence in environment, disinfection procedures, and standardized measurement approaches according to FR/EN/ASTM standards.
- Transgene SAcoreOngoing collaboration since 2016 for development of ANCHOR-tagged oncolytic viruses. Transgene is a biopharmaceutical company developing targeted immunotherapies. NeoVirTech provides high-resolution quantitative microscopy for product visualization and validation.
- SAYENScoreLong-term collaboration with French Technology Transfer Accelerator for development of broad spectrum antivirals for human and animal health. Led to generation of 200+ antiviral variants with nM activity and selectivity indexes over 500, resulting in 2 international patent filings.
- Institut de Recherche Biomédical des Armées (IRBA)coreCollaboration for testing antivirals against poxviruses during 2022 Mpox emergence. Also collaboration for risk mitigation in BSL4 laboratory work with VACV ANCHOR virus.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Neovirtech competitors and assessment
Company assessmentDirect peers
- BIOQUAL: Specialized infectious disease and virology CRO with BSL3 containment for in vivo and in vitro viral studies. Comparable to NeoVirTech in offering virology-specific CRO services to pharma, biotech, and government clients with biosafety-level capabilities.
- ImQuest Biosciences: US-based CRO specializing in virology, antiviral, and infectious disease preclinical services with BSL3 capabilities. Highly comparable to NeoVirTech in virology-focused CRO offering, biosafety-level access, and antiviral screening services for pharma and biotech clients.
- Southern Research: Non-profit CRO with BSL3 facilities and antiviral/infectious disease screening capabilities. Comparable to NeoVirTech in specialized virology CRO work for government and biodefense clients, including pandemic preparedness programs.
Emerging players
- Vir Biotechnology: Clinical-stage immunology company developing antiviral therapies for infectious diseases including influenza, hepatitis B, and HIV. Comparable to NeoVirTech in deep virology expertise and infectious disease focus, though operating as a product developer rather than a CRO.
- VirexpR SAS: French airborne disinfection testing specialist using nebulization chambers. Direct strategic partner to NeoVirTech on airborne poxvirus contamination testing; comparable in disinfection testing focus but specialized on airborne/aerosol delivery rather than live-cell imaging.
- Transgene SA: French biopharmaceutical company developing oncolytic virotherapies and immunotherapies; long-term NeoVirTech partner since 2016. Comparable in that it is a customer and collaborator on ANCHOR-tagged oncolytic virus development, not a direct CRO competitor.
Broad incumbents
- Eurofins Scientific: Global testing services group with virology, disinfection efficacy, and pharma testing offerings. Comparable to NeoVirTech in offering standardized disinfection validation testing (FR/EN/ASTM) and virology testing services, but at much larger scale.
- Evotec SE: European-headquartered drug discovery CRO with antiviral and infectious disease programs. Comparable to NeoVirTech in CRO-based antiviral discovery, but with substantially broader service portfolio and larger bench footprint.
- Charles River Laboratories: Large global preclinical CRO with established virology, BSL3, and antiviral testing services. Comparable to NeoVirTech in offering antiviral discovery and biosafety-level laboratory services, but operates at vastly greater scale and across many therapeutic areas beyond virology.
- Inotiv Inc: Preclinical CRO offering research models, toxicology, and discovery services including infectious disease work. Comparable to NeoVirTech in preclinical CRO services for life sciences clients, though broader in scope and without the proprietary imaging moat.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neovirtech social profiles
Digital presenceNeovirtech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neovirtech leadership team
Management profileNumber of profiles
Profiles1 record
Neovirtech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neovirtech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neovirtech
What does Neovirtech do?
NeoVirTech SAS is a contract research organization (CRO) that delivers specialized virology research services, including antiviral drug discovery, oncolytic virotherapy development, disinfection efficacy testing, and live-cell imaging, executed in BSL2 and BSL3 laboratories. Its proprietary ANCHOR™ technology enables real-time visualization of DNA in living cells, supporting both fee-for-service research and technology licensing engagements.
Is Neovirtech a public or private company?
Neovirtech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Neovirtech founded?
Neovirtech was founded in 2014. It employs 1 to 10 people.
Where is Neovirtech based?
Neovirtech is headquartered in Toulouse, France, in the Europe region.
How does Neovirtech make money?
Five revenue lines are on record. CRO Services - Antiviral Discovery is the primary driver. The others are CRO Services - Disinfection Testing, CRO Services - Oncolytic Virus Development, ANCHOR™ Technology Licensing and proprietary Antiviral Compounds.
Who are Neovirtech's main competitors?
Direct peers on record are BIOQUAL, ImQuest Biosciences and Southern Research. Emerging players are Vir Biotechnology, VirexpR SAS and Transgene SA. Broad incumbents are Eurofins Scientific, Evotec SE, Charles River Laboratories and Inotiv Inc.
Does Neovirtech have an API?
No public API is recorded for Neovirtech.
What industry is Neovirtech in?
Neovirtech's product category is Virology Contract Research Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.